Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma | MicrobiomeTrials← Back to trialsNCT07502287
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-03-02Est. Completion: 2027-03-14
Enrollment target: 36 participants Locations- Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
Other microbiome trials you might be interested in
Ganglioneuroblastoma, NodularNeuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care su…
Birmingham, United StatesEst. completion Dec 31, 2029
Recurrent GanglioneuroblastomaRecurrent NeuroblastomaRefractory GanglioneuroblastomaRefractory Neuroblastoma
This phase I/II trial studies the side effects and best dose of iberdomide when given together with chemoimmunotherapy d…
Oakland, United States
Est. completion Sep 30, 2029
Ototoxicity, Drug-Induced
This study will attempt to demonstrate the efficacy of Sodium Thiosulfate (STS) in preventing hearing loss in patients r…
Cincinnati, United StatesCompleted Jan 2027